Amarin | AMRN - SCHULD





SCHULD Veränderung Datum
AbbVie USD 67.5B 67.5B 2025-12
Alnylam Pharmaceuticals USD 1.28B 30.06M 2025-12
Amarin USD 0 0 2025-03
AstraZeneca USD 33.92B 4.3B 2026-03
BioCryst Pharmaceuticals USD 828.6M 510K 2024-12
DBV Technologies USD 8.59M 295K 2025-09
Esperion Therapeutics USD 262.92M 1.76M 2024-09
GlaxoSmithKline GBP 19.06B 1.34B 2026-03
Halozyme Therapeutics USD 1.51B 1.66M 2025-09
Heron Therapeutics USD 149.65M 157K 2024-09
Ionis Pharmaceuticals USD 2.34B 9.5M 2026-03
Nektar Therapeutics USD 0 0 2022-06
Neurocrine Biosciences USD 428.4M 10.7M 2025-09
Novartis USD 35.38B 2.74B 2025-12